1. Home
  2. FOR vs CTY Comparison

FOR vs CTY Comparison

Compare FOR & CTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forestar Group Inc

FOR

Forestar Group Inc

N/A

Current Price

$24.02

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

CTY

City Therapeutics Inc. Common Stock

N/A

Current Price

$18.54

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FOR
CTY
Founded
2005
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2007
2026

Fundamental Metrics

Financial Performance
Metric
FOR
CTY
Price
$24.02
$18.54
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $34.00
N/A
AVG Volume (30 Days)
177.3K
★ 214.1K
Earning Date
10-29-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.63
N/A
Revenue
★ $1,662,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.43
N/A
P/E Ratio
$14.75
★ N/A
Revenue Growth
★ 10.14
N/A
52 Week Low
$22.81
$15.81
52 Week High
$32.06
$22.65

Technical Indicators

Market Signals
Indicator
FOR
CTY
Relative Strength Index (RSI) 41.24 38.35
Support Level N/A $15.81
Resistance Level $26.36 $22.65
Average True Range (ATR) 0.92 1.70
MACD -0.09 -0.34
Stochastic Oscillator 17.46 39.91

Price Performance

Historical Comparison
FOR
CTY

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

About CTY City Therapeutics Inc. Common Stock

City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.

Share on Social Networks: